Trial reportBiomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia2026
Cannabidiol-hyaluronic acid combination delivered rectally for attenuating abacterial prostatitis symptoms: Single-arm open-label pilot clinical trial.
Trial report in Biomedical papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundChronic nonbacterial prostatitis/chronic pelvic pain syndrome (CP/CPPS) is a prevalent urological disorder with a significant impact on quality-of-life. This study assessed the effects of rectal administration of dual cannabidiol (CBD)/hyaluronic acid (HA)-based therapy in men with CP/CPPS.
methodsA single-arm, open-label pilot trial on 16 men (24-49 years) with CP/CPPS (NIH Chronic Prostatitis Symptom Index [NIH-CPSI] >10, pain subscore ≥4). The participants self-administered rectal CANNEFF® suppositories containing CBD (100 mg) and HA (6.6 mg) as active ingredients, nightly for 30 days. Outcome measures included changes in NIH-CPSI total score, International Prostate Symptom Score (IPSS), and International Index of Erectile Function (IIEF-5). Safety and tolerability were also assessed.
resultsThe median baseline NIH-CPSI score was 24.5 points (range 11, 39) decreasing to a median 20.0 (range 2, 26) at day 30 (P=0.003), with a median reduction of 7.0 points (range -20.0, 6.0). Symptom improvement was found in 81.3 % (13/16) of participants. The IPSS total score decreased from a median of 14.0 points (range 4, 32) to a median 12.0 (range 3, 18) (P=0.033), with voiding symptoms showing the largest improvement. The IIEF-5 score increased modestly but without statistical significance. No adverse events were reported.
conclusionsThe administration of the suppositories with CBD/HA action demonstrated potential symptom relief in CP/CPPS with a favourable tolerability profile. A more nuanced analysis of NIH-CPSI changes and IPSS and IIEF-5 data suggests a clinically meaningful benefit for most participants.
Indexed as
Identifiers
41709732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.